新诊断卵巢癌女性的预后与条件生存
基于美国肿瘤中心6778例卵巢癌女性的纵向数据,计算在既往总生存或无进展生存条件下的条件生存率。中位总生存58.0个月,中位真实世界无进展生存18.4个月;已存活5年者调整后5年条件生存率升至66.4%。结论认为条件生存概念可扩展至同时以无进展时间为条件。
要点
- 中位总生存58.0个月,中位真实世界无进展生存18.4个月。
- 已存活5年者调整后5年条件生存率为66.4%,高于已存活6个月者的48.5%。
- 无进展生存事件5年者调整后5年条件生存率为85.0%,高于6个月无事件者的53.7%。
核心结论
- 本分析将条件生存概念扩展至同时以无进展时间为条件。
- 真实世界无进展生存时间较长的患者,其生存时间长于无进展生存时间较短的患者。
研究设计与样本
- 使用美国肿瘤中心的纵向数据集,纳入6778例卵巢癌女性。
- 计算自一线化疗开始后既往0.5至5年无死亡或无疾病进展事件条件下,额外存活1年或5年的Kaplan-Meier条件生存率。
- 基于多因素Cox回归对与总生存相关的因素进行调整。
主要发现
- 自一线治疗开始至数据截止(2021年2月17日)的中位研究随访为9年(范围1至44年)。
- 中位总生存为58.0个月(95%CI 54.9至60.8),中位真实世界无进展生存为18.4个月(95%CI 17.4至19.4)。
- 调整后1年条件生存率不随已存活时间变化,而已存活6个月者的调整后5年条件生存率为48.5%(95%CI 47.0%至50.1%),已存活5年者升至66.4%(95%CI 63.3%至69.6%),即总计存活10年。
- 6个月时无真实世界无进展生存事件者的调整后1年条件生存率为90.4%(95%CI 89.5%至91.4%),5年时无事件者升至97.6%(95%CI 96.4%至98.8%)。
- 6个月时无真实世界无进展生存事件者的调整后5年条件生存率为53.7%(95%CI 52.0%至55.5%),5年时无事件者升至85.0%(95%CI 81.2%至88.9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: An important question in determining long-term prognosis for women with ovarian cancer is whether risk of death changes the longer a woman lives. Large real-world datasets permit assessment of conditional survival (CS) given both prior overall survival (OS) and real-world progression-free survival (rwPFS). METHODS: Using a longitudinal dataset from US oncology centers, this study included 6778 women with ovarian cancer. We calculated CS rates as the Kaplan-Meier probability of surviving an additional 1 or 5 years, given no mortality (OS) or disease progression (rwPFS) event in the previous 0.5-5 years since first-line chemotherapy initiation, adjusted for factors associated with OS based on multivariable Cox regression. RESULTS: Median study follow-up was 9 years (range, 1-44) from first-line initiation to data cutoff (17-Feb-2021). Median OS was 58.0 months (95% CI, 54.9-60.8); median rwPFS was 18.4 months (17.4-19.4). The adjusted 1-year CS rate (ie, rate of 1 year additional survival) did not vary based on time alive, whereas the adjusted 5-year CS rate increased from 48.5% (47.0%-50.1%) for women who had already survived 6 months to 66.4% (63.3%-69.6%) for those already surviving 5 years (thus surviving 10 years total). The adjusted 1-year CS rate increased from 90.4% (89.5%-91.4%) with no rwPFS event at 6 months to 97.6% (96.4%-98.8%) with no rwPFS event at 5 years; adjusted 5-year CS rate increased from 53.7% (52.0%-55.5%) to 85.0% (81.2%-88.9%), respectively. CONCLUSIONS: This analysis extends the concept of CS by also conditioning on time progression-free. Patients with longer rwPFS experience longer survival than patients with shorter rwPFS.
引用
- Szamreta EA, Monberg MJ, Desai KD, et al. Prognosis and conditional survival among women with newly diagnosed ovarian cancer. Gynecol Oncol. 2024. PMID: 38211405. doi:10.1016/j.ygyno.2023.11.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。